Table 1 Agents in clinical trials for PD.

TargetActionAgentTrial phaseClinical trial identifier
LRRK2Decrease LRRK2 kinase
activity
Denali—DNL-151Phase 1NCT04056689
Denali—DNL-201Phase 1NCT03710707
GlucocerebrosidaseChemical chaperone to
translocate mutant enzyme
from the endoplasmic
reticulum into lysosomes
AmbroxolPhase 2NCT02941822 and NCT02914366
Allergan—LTI-291Phase 1Netherlands Trial NL7061
Block accumulation of the
glucocerebrosidase
substrate, glucosylceramide
Genzyme/Sanofi—Ibiglustat
(GZ/SAR40267)
Phase 2NCT02906020
α-SynucleinAnti–α-synuclein monoclonal
antibodies to lower
α-synuclein concentrations
and block cell-to-cell
transmission
Biogen—CinpanemabPhase 1/2NCT03318523 and NCT03716570
Hoffmann–La Roche/Prothena—
Prasinezumab
Phase 2NCT03100149
Abbvie—ABBV 0805Phase 1NCT04127695
Takeda/AstraZeneca—MEDI1341Phase 1NCT03272165
Lundbeck—Lu-AF-82422Phase 1NCT03611569
Inhibitors of pathological
α-synuclein aggregation
Enterin—ENT-01Phase 1NCT03938922
Alterity Therapeutic—
PBT434
Phase 1U1111–1211-0052
Neuropore Therapies Inc./UCB
S.A.—NPT200-11
Phase 1NCT02606682
c-Abl kinasec-Abl kinase inhibitionSPARC—K0706Phase 2NCT03655236
Novartis—NilotinibPhase 2NCT02954978 and NCT03205488
1ST Biotherapeutics, Inc—FB-101Phase 1NCT04165837
GLP-1 receptorGLP-1 receptor agonist,
decreases inflammation
Amylin Pharmaceutical/
AstraZeneca—Exenatide
Phase 3NCT03456687,
NCT04154072, and
ISRCTN14552789
Novo Nordisk—LiraglutidePhase 2NCT02953665
Sanofi—LixisenatidePhase 2NCT03439943
Neuraly—NLY01Phase 2NCT04154072